Skip to Content Facebook Feature Image

Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeutics

Business

Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeutics
Business

Business

Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeutics

2026-11-16 18:02 Last Updated At:18:10

SAN DIEGO--(BUSINESS WIRE)--Nov 16, 2026--

Seawolf Therapeutics (“Seawolf”) today announced its emergence from stealth, having raised $100 million to transform patient outcomes through the use of its proprietary DNA delivery platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116723769/en/

Founding investor Versant Ventures led the seed round, followed by the Series A financing with Versant, MPM BioImpact, and Novartis Venture Fund (NVF), and participation from Eli Lilly and Company, CRISPR Therapeutics AG, Sixty Degree Capital, Alexandria Venture Investments, Pathway to Cures (the philanthropic venture arm of the National Bleeding Disorders Foundation), and others.

Seawolf also announced a multi-target research collaboration and exclusive license agreement with Sanofi to develop undisclosed therapies for bleeding disorders and additional unnamed indications for up to $1.2 billion in research, development & commercial milestones, as well as tiered royalties on sales of any products resulting from the collaboration.

“Seawolf is charting a new course in patient care through LNP-based DNA medicines,” said Elizabeth Alcamo, Ph.D., president and CEO. “With a strong syndicate of investors and our collaboration with Sanofi, we are well-positioned to execute on our next stage of growth, which will include advancing our lead program for metabolic diseases and collaborating with Sanofi in its mission to develop therapies for patient unmet needs.”

The funds will be used to advance Seawolf’s portfolio of therapeutics that leverage its redosable lipid nanoparticle (LNP)-based DNA delivery system, TRIDENT™ ( T argeted R NA- I nduced D NA E xpression via N uclear T ranslocation). TRIDENT matches the potency, redosability, safety and scalability of RNA-based LNP therapies but overcomes their short-lived expression by delivering DNA-based payloads. To do so, the TRIDENT system consists of a proprietary LNP carrying an immune quiet DNA that encodes a therapeutic transgene and an auxiliary factor that facilitates nuclear access. Therapies built with the TRIDENT technology are potent, durable, have a clean safety profile in primates and -- unlike virus-based DNA platforms -- are redosable, providing the ability to fine-tune or supplement dosing through repeat administration.

The TRIDENT system can be deployed across a broad range of therapeutic areas, including replacing mutant genes and expressing biologics systemically. The company has demonstrated proof-of-concept of the applicability of the technology in both primates and murine preclinical models of metabolic and rare diseases.

“Nucleic acid-based therapies have advanced dramatically over the past decade,” said Tom Woiwode, Ph.D., managing director at Versant and chair of Seawolf’s board. “The Seawolf team is now delivering on the promise of using DNA to drive robust and long-term expression of therapeutic proteins directly from the patient’s own cells. I look forward to seeing this groundbreaking technology transform treatment options for patients.”

About Seawolf Therapeutics

Seawolf Therapeutics is a privately held biotechnology company dedicated to transforming patient outcomes through the use of its proprietary LNP-based DNA delivery platform. The company’s TRIDENT™ technology achieves the elusive goal of delivering DNA into the nucleus of cells to enable the long-term, stable expression of therapeutic proteins, using a non-immunogenic and redosable format. Headquartered in San Diego, CA, the company is backed by top-tier investors including Versant Ventures, MPM BioImpact, and Novartis Venture Fund. For more information, visit www.seawolftx.com or follow us on LinkedIn.

Elizabeth Alcamo, PhD, president and CEO, Seawolf Therapeutics

Elizabeth Alcamo, PhD, president and CEO, Seawolf Therapeutics

Russia is demanding the ice hockey world junior championships are moved out of Canada after the International Ice Hockey Federation ruled its team out of the tournament.

Russian officials are appealing to the International Olympic Committee to intervene on their behalf against the IIHF, with Sports Minister Mikhail Degtyaryov calling for “consequences” which would affect Canada hosting future sports events.

With just over a month until teams arrive in Edmonton and Red Deer for the Dec. 26-Jan. 5 world juniors, the IIHF confirmed Sunday that Russia was out of the tournament, after the Canadian government said it would not allow Russian participation.

“The only legitimate decision would be to move the tournament out of Canada to a country which is prepared to ensure the participation of all eligible national teams including Russia,” Degtyaryov, who also heads the Russian Olympic Committee, posted on social media late Sunday.

“We are convinced that the actions of the IIHF, Hockey Canada and the Canadian government should receive the very toughest assessment from the IOC, international sports organizations, and bring about consequences for their status and the right to host international competitions.”

The Russian hockey federation said the IIHF decision was made “solely due to political reasons, in violation of a binding and effective ruling by the Court of Arbitration for Sport,” and indicated it wanted compensation.

The IOC did not immediately respond to a request for comment Monday after the Russian demands.

Canada's block on Russia followed a ruling from the Court of Arbitration for Sport which overturned an IIHF ban on Russian national teams which had been in place since shortly after Russia invaded Ukraine in 2022.

The CAS ruling has prompted a backlash in hockey. Seven European nations at the 16-team men's world championships have said they will not play against Russia in the tournament in May, and Germany is weighing up whether it can continue as host.

The IIHF is also facing pressure from sponsors who don't want their brands associated with the Russian team.

Besides Canada, governments in Finland, Sweden and Norway have all either tightened their border controls to bar entry to Russian athletes, or have said they are planning to do so.

See AP’s full sports coverage here

FILE - Team of Russia players celebrate during the Ice Hockey World Championship group A match between the Russia and Czech Republic at the Olympic Sports Center in Riga, Latvia, May 21, 2021. (AP Photo/Oksana Dzadan, File)

FILE - Team of Russia players celebrate during the Ice Hockey World Championship group A match between the Russia and Czech Republic at the Olympic Sports Center in Riga, Latvia, May 21, 2021. (AP Photo/Oksana Dzadan, File)

Recommended Articles